Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com - Investec upgraded Persistent Systems Ltd. (PSYS:IN) stock rating from Sell to Hold on Thursday, while raising its price target to INR5,825.00 from INR5,470.00.
The upgrade follows Persistent’s consistent delivery of high growth despite a weak market environment, with performance significantly outpacing its peers. Previous concerns about potentially weakening growth in Healthcare & Life Sciences (HLS), which represents approximately 25% of the company’s revenue, have been addressed by strong quarterly results.
Persistent’s HLS segment grew by 4% quarter-over-quarter, while deal wins reached their highest level with net new annual contract value at US$254 million, representing 16% year-over-year growth. These results effectively addressed earlier concerns about the company’s growth trajectory.
The company’s EBIT margin improved by approximately 80 basis points quarter-over-quarter to 16.3%, positioning it well to deliver margin improvement exceeding 100 basis points in fiscal year 2026. Management indicated they are on track to achieve another 100 basis points of EBIT margin expansion in fiscal year 2027.
Based on these developments, Investec increased its earnings per share estimates for Persistent Systems by 4%, 1.6%, and 4.8% for fiscal years 2026, 2027, and 2028, respectively, while rolling over valuations to Q3FY28E TTM.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.